• 1
    Hoofnagle JH (1997) Hepatitis C: the clinical spectrum of disease. Hepatology 26, 15S20S.
  • 2
    Manns MP, Cornberg M & Wedemeyer H (2001) Current and future treatment of hepatitis C. Indian J Gastroenterol 20 (Suppl. 1), C47C51.
  • 3
    Pasquinelli AE, Ernst RK, Lund E, Grimm C, Zapp ML, Rekosh D, Hammarskjold ML & Dahlberg JE (1997) The constitutive transport element (CTE) of Mason-Pfizer monkey virus (MPMV) accesses a cellular mRNA export pathway. EMBO J 16, 75007510.
  • 4
    Tang H, Gaietta GM, Fischer WH, Ellisman MH & Wong-Staal F (1997) A cellular cofactor for the constitutive transport element of type D retrovirus. Science 276, 14121415.
  • 5
    Gruter P, Tabernero C, von Kobbe C, Schmitt C, Saavedra C, Bachi A, Wilm M, Felber BK & Izaurralde E (1998) TAP, the human homolog of Mex67p, mediates CTE-dependent RNA export from the nucleus. Mol Cell 1, 649659.
  • 6
    Braun IC, Rohrbach E, Schmitt C & Izaurralde E (1999) TAP binds to the constitutive transport element (CTE) through a novel RNA-binding motif that is sufficient to promote CTE-dependent RNA export from the nucleus. EMBO J 18, 19531965.
  • 7
    Tang H & Wong-Staal F (2000) Specific interaction between RNA helicase A and Tap, two cellular proteins that bind to the constitutive transport element of type D retrovirus. J Biol Chem 275, 3269432700.
  • 8
    Sullenger BA & Cech TR (1993) Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science 262, 15661569.
  • 9
    Bertrand E, Castanotto D, Zhou C, Carbonnelle C, Lee NS, Good P, Chatterjee S, Grange T, Pictet R, Kohn D et al. (1997) The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA 3, 7588.
  • 10
    Frese M, Barth K, Kaul A, Lohmann V, Schwarzle V & Bartenschlager R (2003) Hepatitis C virus RNA replication is resistant to tumour necrosis factor-alpha. J Gen Virol 84, 12531259.
  • 11
    Warashina M, Kuwabara T, Kato Y, Sano M & Taira K (2001) RNA-protein hybrid ribozymes that efficiently cleave any mRNA independently of the structure of the target RNA. Proc Natl Acad Sci USA 98, 55725577.
  • 12
    Hagiwara S, Nakamura K, Hamada H, Sasaki K, Ito Y, Kuribayashi K, Sato T, Sato Y, Takahashi M, Kogawa K et al. (2003) Inhibition of type I procollagen production by tRNAval CTE-HSP47 ribozyme. J Gene Med 5, 784794.
  • 13
    Nawrot B, Antoszczyk S, Maszewska M, Kuwabara T, Warashina M, Taira K & Stec WJ (2003) Efficient inhibition of beta-secretase gene expression in HEK293 cells by tRNAval-driven and CTE-helicase associated hammerhead ribozymes. Eur J Biochem 270, 39623970.
  • 14
    Welch PJ, Tritz R, Yei S, Barber J & Yu M (1997) Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther 4, 736743.
  • 15
    Krüger M, Beger C, Welch PJ, Barber JR, Manns MP & Wong-Staal F (2001) Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation. Mol Cell Biol 21, 83578364.
  • 16
    Tischendorf JJW, Beger C, Korf M, Manns MP & Krüger M (2004) Polypyrimidine tract-binding protein (PTB) inhibits hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation, but does not affect HCV replication. Arch Virol 149, 19551970.
  • 17
    Yu M, Ojwang J, Yamada O, Hampel A, Rapapport J, Looney D & Wong-Staal F (1993) A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90, 63406344.
  • 18
    Welch PJ, Tritz R, Yei S, Leavitt M, Yu M & Barber J (1996) A potential therapeutic application of hairpin ribozymes: in vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther 3, 9941001.
  • 19
    Koseki S, Tanabe T, Tani K, Asano S, Shioda T, Nagai Y, Shimada T, Ohkawa J & Taira K (1999) Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III. J Virol 73, 18681877.
  • 20
    Kato Y, Kuwabara T, Warashina M, Toda H & Taira K (2001) Relationships between the activities in vitro and in vivo of various kinds of ribozyme and their intracellular localization in mammalian cells. J Biol Chem 276, 1537815385.
  • 21
    Beger C, Krüger M & Wong-Staal F (1998) Ribozymes in cancer gene therapy. Gene Therapy of Cancer (LattimeEC & Gerson, SJ, eds), pp. 139152. Academic Press, San Diego, CA.
  • 22
    James HA & Gibson I (1998) The therapeutic potential of ribozymes. Blood 91, 371382.
  • 23
    Krüger M, Beger C & Wong-Staal F (1999) Use of ribozymes to inhibit gene expression. Methods Enzymol 306, 207225.
  • 24
    Muotri AR, da Veiga Pereira L, dos Reis Vasques L & Menck CF (1999) Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function. Gene 237, 303310.
  • 25
    Welch PJ, Barber JR & Wong-Staal F (1998) Expression of ribozymes in gene transfer systems to modulate target RNA levels. Curr Opin Biotechnol 9, 486496.
  • 26
    Honda M, Beard MR, Ping LH & Lemon SM (1999) A phylogenetically conserved stem-loop structure at the 5′ border of the internal ribosome entry site of hepatitis C virus is required for cap-independent viral translation. J Virol 73, 11651174.
  • 27
    Blight KJ & Rice CM (1997) Secondary structure determination of the conserved 98-base sequence at the 3′ terminus of hepatitis C virus genome RNA. J Virol 71, 73457352.
  • 28
    Good PD, Krikos AJ, Li SX, Bertrand E, Lee NS, Giver L, Ellington A, Zaia JA, Rossi JJ & Engelke DR (1997) Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther 4, 4554.
  • 29
    Takeda K & Akira S (2005) Toll-like receptors in innate immunity. Int Immunol 17, 114.
  • 30
    Korf M, Jarczak D, Beger C, Manns MP & Krüger M (2005) Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. J Hepatol 43, 225234.